Literature DB >> 16354886

Obesity and migraine: a population study.

Marcelo E Bigal1, Joshua N Liberman, Richard B Lipton.   

Abstract

OBJECTIVE: To assess the influence of body mass index (BMI) on the prevalence, attack frequency, and clinical features of migraine.
METHODS: In a population-based telephone interview study, the authors gathered information on headache, height, and weight. The 30,215 participants were divided into five categories, based on BMI: 1, underweight (< 18.5), normal weight (18.5 to 24.9), overweight (25 to 29.9), obese (30 to 24.9), and morbidly obese (> or = 35). Migraine prevalence and modeled headache features were assessed as a function of BMI, adjusting by covariates (age, sex, marital status, income, medical treatment, depression).
RESULTS: Subjects were predominantly female (65% female) and in middle life (mean age 38.4). BMI group was not associated with the prevalence of migraine, but was associated with the frequency of headache attacks. In the normal weight group, 4.4% had 10 to 15 headache days per month, increasing to 5.8% of the overweight (odds ratio [OR] = 1.3), 13.6% of the obese (OR = 2.9), and 20.7% of the morbidly obese (OR = 5.7). The proportion of subjects with severe headache pain increased with BMI, doubling in the morbidly obese relative to the normally weighted (OR = 1.9). Similar significant associations were demonstrated with BMI category for disability, photophobia, and phonophobia.
CONCLUSION: Though migraine prevalence is not associated with body mass index, attack frequency, severity, and clinical features of migraine increase with body mass index group.

Entities:  

Mesh:

Year:  2005        PMID: 16354886     DOI: 10.1212/01.wnl.0000197218.05284.82

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  113 in total

Review 1.  Obesity and chronic daily headache.

Authors:  Marcelo E Bigal; Alan M Rapoport
Journal:  Curr Pain Headache Rep       Date:  2012-02

2.  Chronic daily headache, medication overuse, and obesity in children and adolescents.

Authors:  Ann Pakalnis; Donna Kring
Journal:  J Child Neurol       Date:  2011-09-27       Impact factor: 1.987

Review 3.  Migraine and cardiovascular diseases.

Authors:  G Pierangeli; G Giannini; V Favoni; L Sambati; S Cevoli; P Cortelli
Journal:  Neurol Sci       Date:  2012-05       Impact factor: 3.307

Review 4.  Migraine and metabolism.

Authors:  G Casucci; V Villani; D Cologno; F D'Onofrio
Journal:  Neurol Sci       Date:  2012-05       Impact factor: 3.307

5.  Higher augmentation index is associated with tension-type headache and migraine in middle-aged/older humans with obesity.

Authors:  Graziela Z Kalil; Ana Recober; Ann Hoang-Tienor; Miriam Bridget Zimmerman; William G Haynes; Gary L Pierce
Journal:  Obesity (Silver Spring)       Date:  2016-02-05       Impact factor: 5.002

6.  Metabolic syndrome and insulin resistance in migraine.

Authors:  Sanjeev K Bhoi; Jayantee Kalita; Usha K Misra
Journal:  J Headache Pain       Date:  2012-01-26       Impact factor: 7.277

7.  Episodic migraine and obesity and the influence of age, race, and sex.

Authors:  B Lee Peterlin; Andrea L Rosso; Michelle A Williams; Jason R Rosenberg; Jennifer A Haythornthwaite; Kathleen R Merikangas; Rebecca F Gottesman; Dale S Bond; Jian-Ping He; Alan B Zonderman
Journal:  Neurology       Date:  2013-09-11       Impact factor: 9.910

8.  Evaluating obesity in fibromyalgia: neuroendocrine biomarkers, symptoms, and functions.

Authors:  Akiko Okifuji; David H Bradshaw; Chrisana Olson
Journal:  Clin Rheumatol       Date:  2009-01-27       Impact factor: 2.980

9.  Predictors of Prolonged Hospital Stay in Status Migrainosus.

Authors:  S Y Modi; D Dharaiya; A M Katramados; P Mitsias
Journal:  Neurohospitalist       Date:  2016-04-05

Review 10.  Bypassing TBI: Metabolic Surgery and the Link between Obesity and Traumatic Brain Injury-a Review.

Authors:  T W McGlennon; J N Buchwald; Walter J Pories; Fang Yu; Arthur Roberts; Eric P Ahnfeldt; Rukmini Menon; Henry Buchwald
Journal:  Obes Surg       Date:  2020-10-30       Impact factor: 4.129

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.